Irinotecan chemotherapy seeds for glioblastoma
Part of Cancer clinical trials.
This trial tests a new way to deliver chemotherapy directly into the brain after surgery for glioblastoma. Tiny seeds containing irinotecan are placed in the tumor cavity during surgery, aiming to kill remaining cancer cells while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that can be surgically removed, either a first-time diagnosis or a return of the tumor.
- You are 18 years or older.
- You are healthy enough for surgery and have good kidney, liver, and blood cell counts.
- You have not had prior chemotherapy with irinotecan in the last year (if this is a new diagnosis).
- You do not have widespread tumor spread or more than one distinct tumor location.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial is testing a new way to find and remove glioblastoma brain tumors using a special MRI scan. It may help doctors remove more of the tumor safely during surgery.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.